ENSC
Ensysce BiosciencesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
If Nasdaq accepts the plan and PF614-301 keeps advancing, the stock can still re-rate sharply because the current equity base is tiny and any clinical de-risking would matter disproportionately.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Cash and cash equivalents were only $745,482 at 2026-03-31, versus $4.31 million at 2025 year-end, and management says cash only funds operations into late Q2 2026 [#10-Q-2026-05-15].
Momentum
81
Value
41
Sentiment
25
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.18 · Bull $0.85 · Bear $0.05
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-16 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-30 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $16.45
Why
Momentum81 · Δ7d -
Value41 · Δ7d -0.1
Sentiment25 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
81
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
25
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 81.5 / Value 41.1 / Sentiment 24.9
Fundamentals (TTM)As of 2026-07-16
Fundamentals (TTM)
As of 2026-07-16
Market Cap
$4.26M
Beta
1.18
Shares Out
15.37M
P/E (TTM) · Derived
-0.1
P/S (TTM)
0.82
P/FCF (TTM) · Derived
-0.10
Rev YoY
-27.2%
EPS YoY
-62.6%
Gross Margin
+100.0%
Op Margin
-245.9%
Net Debt
-$4.03M
Current Ratio
0.71
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology